Angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers for diabetic nephropathy: a retrospective comparison

Abstract

Introduction. There are no adequate head-tohead comparisons of angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARB) in type 2 diabetic patients in spite of some interesting attempts. Furthermore, there are no adequate studies about the effects of ACE inhibitors in type 2 diabetic patients, who are the great majority of diabetic individuals. This study has retrospectively compared the effects of ACE inhibitors and ARBs used to treat diabetic nephropathy in a group of type 2 diabetic subjects. Design and methods. Patients (n=154) were treated with ACE inhibitors (mean age 59.5±13.3 years, 52.6% were male). Eighty-five patients had been treated with ARBs from 1999 until now (mean age 62.6±10.9 years, 56.0% were male, differences not significant). Kaplan-Meier survival analysis was used to calculate survival before reaching end-stage renal disease (ESRD) (glomerular filtration < 15 ml/min, stage V of renal disease as defined by KDOQI clinical guidelines) or starting renal replacement therapy. Only patients treated for more than six months were included in the survival analysis.Comparison of survival was made at three, five and seven years after starting treatment. Results. Pre-ESRD survival was 91.9% at three years, 81.6% at five years and 61.9% at seven years of follow-up for patients treated with ACE inhibitors. For patients treated with ARBs, pre-ESRD survival was 95.3% at three years, 82.1% at five years and 78.2% at seven years of follow-up (p=0.02, log-rank test). At 36 months, the comparative odds ratio for having started renal replacement therapy or reaching end-stage renal failure was 0.246 (95% confidence interval 0.114-0.531, p<0.001 for chi-square and likelihood ratio tests). The risk for the ARB cohort was 0.682 (95% confidence interval 0.578-0.804), meanwhile for ACE inhibitor patients it was 2.768 (95% confidence interval 1.481-5.172). Conclusions. The effects of ACE inhibitors andARBs seem to be different, favouring the use of ARBs. These results may have been influenced by the different circumstances when each kind of drug was indicated, since ARBs were used with the specific recommendations for control of blood pressure in diabetic patients. An earlier referral of these patients may also have had some effect on these results. The need for a well-designed prospective study on type 2 diabetic patients with heavy proteinuria is warranted.

A network analysis to compare biomarker profiles in patients with and without diabetes mellitus in acute heart failure

“…It is unclear whether ACEi target the periostin pathway. While there are no direct head to head comparisons of ACEi and ARBs in patients with diabetes and HF, comparative analyses have suggested that ARBs may be superior to ACEi in the setting of diabetic nephropathy . Studies evaluating strategies that target the periostin pathway, with ARBs or other therapies, may represent a future direction of research among patients with diabetes and HF.…”

Применение Препаратов Группы Блокаторов Рецепторов Ангиотензина В Комплексной Терапии Пациентов С Гипертонической Болезнью И сахарным Диабетом

“…По этой причине обе группы препаратов в обя-зательном порядке входят, в частности, в рекомен-дации Best Practice от 21.10.2013 по лечению диа-бетической нефропатии [4].…”

The Use of Renin-Angiotensin System Blockades Among Patients with Chronic Kidney Disease

“…However, in hypovolemic patients, ACEIs/ARBs might cause acute renal failure as they cause vasoconstriction of the efferent arteriole; hence, careful attention is required in this group of patients. 9,10 12 On the other hand, non-significant differences in renal protective effects between captopril and nifedipine were observed among non-diabetic CKD patients. 13 The researcher was interested in investigating in-depth the theoretical background and knowledge, clinical attitudes and daily practices of the physicians from different specialties in Iraq regarding the use of RAS blockers in CKD patients.…”